Medicamen Biotech Limited

MEDICAMEQ

INE646B01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:51 31/05/2024 BST			5-day change	1st Jan Change
500.6 ^INR	+4.18%		-3.45%	-16.90%

05-31	Medicamen Biotech Receives Observations from Greek Regulatory Body; Shares Up 4%	MT
05-29	Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Medicamen Biotech Limited Recommends Dividend for the Financial Year 2019-20

June 30, 2020 at 11:54 am

Medicamen Biotech Limited announced at its board meeting held on June 30, 2020, the board has recommended a final dividend @5% on equity shares of INR 10 each that is 50 paise per equity share for the financial year 2019-20.

Latest news about Medicamen Biotech Limited

Medicamen Biotech Receives Observations from Greek Regulatory Body; Shares Up 4%	05-31	MT
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-29	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-10	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/08/23	CI
Medicamen Biotech Limited Recommends Final Dividend for Financial Year 2022-23	29/05/23	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/05/23	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/02/23	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/11/22	CI
INDIA STOCKS-Indian shares seen opening higher as global equities attempt bounce	04/10/22	RE
Medicamen Biotech Forays into Domestic Indian Pharmaceutical Business	04/10/22	MT
Medicamen Biotech Forms New Unit	26/08/22	MT
Medicamen Biotech Ties Up with Danish Pharmaceutical Firm for Manufacturing of Drugs	12/08/22	MT
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/08/22	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	25/05/22	CI
Medicamen Biotech Limited Recommends Final Dividend for the Financial Year 2021-22	25/05/22	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	08/02/22	CI
Promoter Group Narrows Stake in Medicamen Biotech	04/01/22	MT
Promoter Group Lowers Stake in Medicamen Biotech to 2.93%	10/12/21	MT
Medicamen Biotech's Consolidated Net Profit Climbs in Fiscal Q2	05/11/21	MT
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	03/11/21	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	13/08/21	CI
Medicamen Biotech Limited Recommends Final Dividend for the Fiscal Year 2021	26/06/21	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	26/06/21	CI
Medicamen Biotech : Shivalik Rasayan Boosts Stake in Medicamen Biotech to 41.79%	24/03/21	MT

Chart Medicamen Biotech Limited

Duration

Period

More charts

Company Profile

Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICAMEN BIOTECH LIMITED	-16.90%	76.27M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B